Oct 31 (Reuters) - Ametek (AME.N), which makes electronic instruments, raised its full-year forecast on Tuesday and announced its fifth and sixth acquisitions for 2023 as it expands into different markets and drives earnings growth.
Jeff Aronin’s Harmony Biosciences is ringing in a new financing agreement, one that’s bringing in hundreds of millions of dollars.
Analyst increases estimate of revenue potential of Catalent’s gene therapy unit in light of ‘insatiable’ demand.
Drug developer Catalent Inc has agreed to buy privately held, gene-therapy focused Paragon Bioservices Inc for $1.2 billion, the Wall Street Journal reported on Sunday, citing people familiar with the matter.